Barr Pharmaceuticals, Inc. announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the US Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s Camptosar (irinotecan hydrochloride) injection, 20 mg/mL, packaged in 40 mg/2 mL and 100 mg/5 mL vials.
The company plans to launch its product in the fourth quarter of 2008. Barr's US generic injectable portfolio now totals nine products.
Barr's generic version of Camptosar injection will compete in a market that had total annual sales of approximately $353 million for the twelve months ended August 2008, based on IMS sales data.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.